Sandu Pharmaceuticals Ltd — Board Meeting, 28-05-2025: Board Meeting

Sandu Pharmaceuticals Limited has announced a board meeting to approve the financial results for the quarter and half-year. The company approved audited standalone and consolidated financial results, reflecting revenue from operations of Rs 14.07 Cr for the quarter and Rs 67.19 Cr for the year. Profit before tax stood at Rs 0.34 Cr for the quarter and Rs 2.16 Cr for the year. The company sold its entire stake in its wholly owned subsidiary, Sandu Phytoceuticals Pvt. Ltd., in August 2024, leading to standalone financials from the quarter ended December 2024. The Board proposed a final dividend of Rs 0.80 per share (8%). Swapnil J Dixit & Associates was recommended as Secretarial Auditor for five years, and M/s Shekhar Joshi & Co as Cost Auditor for FY 2025-26. Promoter Akshath Finvest was reclassified to public category. Sandu reported stable operational metrics and maintained net cash flow positivity from operations.